Immunology expert Paul Licciardi, PhD, weighs in on the current state of recommended pneumococcal vaccines and what is on the horizon in the developmental stage.
Paul Licciardi, PhD
Advertisement
Paul Licciardi, PhD, Group Leader of Vaccine Immunology at the Murdoch Children’s Research Institute.
Articles by Paul Licciardi, PhD
In part 2, Paul Licciardi, PhD, dives into the evolving need for updated pneumococcal vaccine recommendations and how pharmacists can keep their patients informed.
In part 1 of our interview with Paul Licciardi, PhD, he addresses the lowered pneumococcal vaccination age as well as the adult population’s overall relationship with immunization.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves XFG-Targeted COVID-19 Vaccines From Multiple Companies
2
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
3
FDA Approves Stelara for Pediatric Ulcerative Colitis
4
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
5